PMID: 9167505Jun 1, 1997Paper

Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group

The American Journal of Psychiatry
D L ZimbroffK B Kashkin

Abstract

This multicenter, double-blind, placebo-controlled study evaluated the efficacy and safety of three doses of sertindole (12, 20, and 24 mg/day) and haloperidol (4, 8, and 16 mg/day) in the treatment of psychotic symptoms for 497 hospitalized patients with schizophrenia. The patients were randomly assigned to one of the medication groups and received treatment for 8 weeks. Changes in Positive and Negative Syndrome Scale, Scale for the Assessment of Negative Symptoms, Brief Psychiatric Rating Scale, and Clinical Global Impression scores were used as evaluations of treatment efficacy. Three rating scales were used to assess extrapyramidal symptoms as well as the occurrence of adverse events and the use of medications related to extrapyramidal symptoms. Both sertindole and haloperidol were comparably effective in the treatment of psychosis, and all dose levels were significantly more effective than placebo. For the treatment of negative symptoms, only sertindole, 20 mg/day, was significantly more effective than placebo. For all extrapyramidal symptom measures, sertindole was clinically and statistically indistinguishable from placebo, and rates of extrapyramidal symptoms were not dose related. All dose levels of haloperidol produce...Continue Reading

Citations

Jul 27, 2002·Psychopharmacology·W Wolfgang Fleischhacker
Oct 6, 2001·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·J M Kane
Jul 30, 2005·Der Nervenarzt·W Haverkamp, M Deuschle
Nov 4, 2006·Der Nervenarzt·W W Fleischhacker, W Hummer
Dec 4, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Herbert Y MeltzerJunji Ichikawa
Dec 4, 1998·Biological Psychiatry·G TsaiJ T Coyle
Jul 21, 2011·Nordic Journal of Psychiatry·Eva LindströmChristophe Sapin
Jun 21, 2006·Expert Review of Neurotherapeutics·Kimberly H LittrellNicole M Wolf
Aug 2, 2014·Expert Opinion on Pharmacotherapy·Maria Rosaria Anna MuscatelloRocco Antonio Zoccali
Aug 24, 2006·Expert Opinion on Pharmacotherapy·Eva Lindström, Sten Levander
Sep 21, 2012·Expert Opinion on Drug Safety·Evangelos KaramatskosDieter Naber
May 20, 2008·Expert Opinion on Drug Metabolism & Toxicology·Edoardo Spina, Rocco Zoccali
Feb 26, 2013·Expert Opinion on Drug Safety·Chi-Un Pae
Jul 28, 2012·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Alkomiet HasanUNKNOWN World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia
Jan 7, 2015·Pharmacology & Therapeutics·Sonali ReisingerDaniela D Pollak
May 31, 2008·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Siegfried Kasper
Feb 5, 2008·Schizophrenia Research·Rajiv TandonUNKNOWN Section of Pharmacopsychiatry, World Psychiatric Association
Nov 13, 2015·Acta Psychiatrica Scandinavica·S D ØstergaardP Bech
Apr 10, 2003·The Psychiatric Clinics of North America·Robin Emsley, Piet Oosthuizen
Apr 10, 2003·The Psychiatric Clinics of North America·André F Joubert
Jan 7, 2011·The International Journal of Neuropsychopharmacology·Stefan LeuchtJohn M Davis
Sep 6, 2008·Progress in Brain Research·Neil M RichtandRobert K McNamara
Feb 5, 2014·Schizophrenia Bulletin·Stefan LeuchtJohn M Davis
Apr 2, 2009·Psychological Medicine·S LeuchtJ M Davis
Jun 10, 2009·Revista brasileira de psiquiatria : orgão oficial da Associação Brasileira de Psiquiatria, Asociación Psiquiátrica de la América Latina·Irismar Reis de OliveiraEduardo Pondé de Sena
Sep 30, 2005·International Clinical Psychopharmacology·Lowijs N M Perquin
Jan 26, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Neil M RichtandRobert K McNamara
Jan 1, 1998·International Journal of Psychiatry in Clinical Practice·J Fritze, B Bandelow
Jan 1, 1999·International Journal of Psychiatry in Clinical Practice·L C KopalaJ S Hellewll

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here